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In human hearts, an extensive pre-existing collateral network is present. This was shown unequivocally some
50 years ago in a series of very detailed post-mortem angiographic studies. In these studies, it was also ob-
served that the pre-existent collateral vessels enlarge upon closure of an epicardial coronary artery, resulting in
large collateral conduit arteries, in sharp contrast to earlier claims that human coronary arteries are functional
end arteries. These insights still form the basis for the concept of arteriogenesis as positive remodeling of pre-
existent arteriolar connections. Subsequent experimental studies disclosed the putative role of circulating cells,
especially monocytes, which invade the proliferating vessel wall and secrete growth factors, degrading enzymes
and survival factors that are required for the development of a mature collateral circulation. Experimental stimu-
lation of arteriogenesis is feasible but to date a relatively low number of clinical studies, with no or limited suc-
cess, have been performed. The use of intracoronary derived collateral flow index can increase the sensitivity to
detect the effects of pharmacological compounds on arteriogenesis, which is important in first proof-of-principle
studies. These invasive measurements also allow the detection of patients with an innate defect in their arterio-
genic response to coronary obstruction. In a reversed bedside-to-bench approach, the characterization of ribonu-
cleic acid and protein expression patterns in these patients generated new targets for therapeutic
arteriogenesis. (J Am Coll Cardiol 2010;55:17–25) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.058h
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alittle more than 50 years ago, the first of a large series of
tudies on the extent of the collateral circulation in the
uman heart was published (1). Using high-resolution
ost-mortem angiography, these studies delivered final
roof of the presence of collateral vessels between the
ifferent vascular territories of the normal healthy human
eart, refuting claims that coronary arteries are functional
nd arteries. These studies also showed that the diameter of
hese pre-existent collateral vessels increases upon coronary
cclusion. This still forms the basis for the concept of
rteriogenesis, which is the development of large caliber
ollateral arteries from a pre-existing network, in response
o arterial occlusive disease.
Experimental studies showed that the increase in diam-
ter of collateral vessels is not passive dilation, but active
roliferation of endothelial as well as smooth muscle cells.
his opened the field for pharmacological modulation of
ollateral vascular development.
Currently, several candidates for pharmacological stimu-
ation of arteriogenesis are known, the tools to measure the
ffects in patients are available, and the first clinical studies
rom the *Department of Cardiology, Academic Medical Center, University of
msterdam, Amsterdam, the Netherlands; †Max Planck Institute for Physiological
nd Clinical Research, Department of Experimental Cardiology, Bad Nauheim,
ermany; and ‡Materia Medica and Therapeutics, University of Glasgow, Glasgow,
cotland. Dr. Fulton is a retired senior lecturer.c
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ccepted June 29, 2009.ave been published. The intracoronary measurements of
ollateral flow in combination with ribonucleic acid mi-
roarray techniques and proteomics now also allow the
dentification of biological pathways that are linked to
nsufficient collateral artery growth. This opens new ways to
nd arteriogenic targets in patients that subsequently can be
ested in validated experimental models. The present review
s dedicated to 5 decades of clinical arteriogenesis research,
ummarizes our current understanding of arteriogenesis from a
istorical perspective, and outlines future developments.
orphology of the Coronary Collateral
irculation in Humans: Post-Mortem Analysis
recise morphology remains the province of post-mortem
ngiography. Some 50 years ago, it was widely believed that
he coronary arteries of humans were end arteries (2).
owever, when using a more precise technique of post-
ortem angiography, it was convincingly demonstrated
hat, in fact, in all human hearts an extensive network is
resent, connecting the different vascular territories of the
eart (3). The contrast medium employed in this technique
onsisted of bismuth oxychloride 20% in gelatin prepared
rom a filtered solution, resulting in a maximal particle size
f 2.0 m and penetration to a minimal lumen diameter of
5 m. Another important aspect for maximal penetration
s pressure control of the injection of the contrast medium
nd nonsimultaneous injection of the left and the right
oronary arteries.
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A Critical Review of Arteriogenesis December 29, 2009/January 5, 2010:17–25Anatomy of pre-existing coronary
anastomoses. In the normal
heart, superficial and deep collat-
eral arteries are present. Superfi-
cial collateral arteries are found
mainly at the interface between
arterial territories, located at the
anterior wall of the right ven-
tricle, between branches of the
left anterior descending artery
(LAD) and the right coronary
artery (RCA), near the posterior
interventricular groove between
the RCA and the left circumflex
artery (LCx) (varying greatly de-
pending on the balance of RCA
and LCx), near the apex between
branches of the LAD and mar-
inal branches of the RCA and LCx, and in the atrial wall.
n contrast to the dog, in humans, superficial collateral
rteries are relatively small in number and caliber (20 to 200
m in the healthy human heart).
Deep collateral arteries are more frequent than the
uperficial collateral arteries and are often of larger caliber
100 to 300 m, sometimes even more). Transventricular
eptal collateral arteries are well recognized, connecting the
AD and the posterior descending artery, arising from
CA or LCx. Transventricular collateral arteries are some-
imes exploited to open chronic total coronary occlusions in
retrograde fashion (4). Collateral arteries in the subendo-
ardial plexus of the left ventricle form a network of
Abbreviations
and Acronyms
CFIp  pressure-derived
collateral flow index
FGF  fibroblast growth
factors
GM-CSF  granulocyte-
macrophage colony-
stimulating factor
LAD  left anterior
descending artery
LCx  left circumflex
artery
MCP  monocyte
chemotactic protein
RCA  right coronary
artery
Figure 1 Coronary Collateral Circulation
(A) Anatomic distribution of pre-existing collateral vessels in the heart. The interve
of collateral vessels. (B) Post-mortem angiogram showing pre-existing collateral ve
presence of obstruction of the left anterior descending artery (LAD) (white circle).
RPL  right posterolateral artery; RV  right ventricle; RVA  right ventricular artentercommunicating arterial channels throughout the free
all, largely conforming to the columnae carneae. They are
ather poorly represented in clinical angiography, possibly
n account of intermittent filling and dilution of contrast
edium. A schematic overview of the anatomic location of
ollateral arteries in the heart is provided in Figure 1.
nlargement of coronary collateral arteries in obstructive
oronary artery disease. Evidence from morphological
tudies is entirely consistent with the concept that the larger
aliber collateral arteries displayed in disease result from
nlargement of pre-existing anastomoses of smaller caliber
n the normal heart. There is no need to postulate new
rterial anastomoses in the human heart. First, there are no
natomic patterns of enlarged collateral arteries in disease
hat do not have their counterparts in the normal heart.
econd, there are sufficient numbers of anastomoses in the
ormal heart to account for the numbers found in disease.
he difference is not in number but in size, showing a shift
o the right regarding vessel diameter (5) (Fig. 2).
schemic myocardial damage and the collateral circulation. It
as long been observed that the extent of ischemic myocar-
ial damage consequent on coronary artery occlusion usually
alls short of the entire arterial territory. The background in
uman coronary disease is extremely heterogeneous with
any factors involved, but the outstanding factor that limits
he extent of myocardial damage following complete coro-
ary occlusion is the degree of development of the collateral
irculation at the time (6). Where there is only a small
ncrease in diameter of collateral arteries, damage tends to
e massive. Moderate enlargement greatly restricts the
xtent of the damage. Where the subendocardial plexus has
lar septum (IVS) (highlighted area) is of special interest, showing a large amount
in absence of coronary artery disease. (C) Outgrowth of collateral vessels in
left circumflex artery; LV  left ventricle; RDP  posterior descending artery;ntricu
ssels
LCx 
ry.
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December 29, 2009/January 5, 2010:17–25 A Critical Review of Arteriogenesisecome a network of wide-bore channels throughout the
nner zone, diffuse subendocardial infarction is characteris-
ic. If total inflow to the coronary system has been curtailed
y multivessel obstruction, the deep network cannot relieve
schemia but it can achieve an equitable distribution of
mpoverished blood supply. Thus, further epicardial artery
cclusion does not result in regional infarction but rather
ubendocardial ischemia and diffuse subendocardial focal
ecrosis. Also, similar damage commonly occurs under
tress of extracoronary factors, such as tachycardia, without
udden occlusion in the severely obstructed main arteries.
itigation of ischemia by augmented collateral blood flow
ersists only as long as the foster arteries remain patent.
hen acute occlusion of the foster artery occurs, infarction
ay not be restricted to its own ipsiregional territory but
ay be extended to the territory of the artery it had been
ustaining hitherto. This phenomenon is called pararegional
nfarction (5).
unctionality of the Coronary Collateral
irculation in Humans: Patient Studies
ngiographic studies. The introduction of coronary an-
iography enabled evaluation of the coronary collateral
irculation in patients. The first clinical studies were based
n angiographic documentation of spontaneously visible
ollateral arteries. A landmark study was performed by
entrop et al. (7) that demonstrated elegantly that the
isualization of collateral arteries markedly depends on the
ressure gradient exerted upon the collateral vasculature,
imilar to post-mortem angiographic studies described ear-
ier. In the majority of patients, collateral arteries, which are
bsent during baseline conditions, become apparent during
alloon coronary occlusion of the recipient artery. These
o-called recruitable collateral arteries are visualized by
sing a second arterial catheter for contrast injection in the
Figure 2 Numerical Distribution of Collateral Arteries in
Patients Either With or Without Obstructive CAD
A shift to the right is recognized in patients with coronary artery disease (CAD),
whereby the absolute number of collateral arteries does not increase but
rather the mean diameter of these vessels increases. Adapted, with permis-
sion, from Fulton (3).oster artery during balloon coronary occlusion. The find- (ngs of Rentrop et al. (7) showed that previous clinical
tudies incorrectly classified the development of collateral
rteries. Spontaneously visible collateral arteries can be
onsidered as “a tip of the iceberg” that leaves a major part
f the collateral vascular network unexplored. Unfortu-
ately, several recently published studies use the Rentrop
core for evaluation of angiograms but without the above-
entioned contrast injection in the foster artery and the
omplete balloon occlusion of the recipient artery.
The presence of recruitable collateral arteries protects
gainst myocardial ischemia and left ventricular dysfunction
uring brief coronary collateral occlusion, indicating func-
ional significance of recruitable collateral arteries (7). Also,
urvival after myocardial infarction is related to the extent of
he collateral circulation (8). Angiographic studies per-
ormed for evaluation of thrombolytic therapy in acute
yocardial infarction showed that collateral arteries that are
nitially absent become apparent within 10 to 14 days
ollowing sustained coronary occlusion (9). A study by
erner et al. (10) indicates that coronary angiography can
e used to assess the functional capacity of collateral arteries
n total coronary occlusions, showing that angiographic
rading of collateral connections is related to the preserva-
ion of regional left ventricular function and invasively
ssessed parameters of collateral hemodynamics. The ad-
antage of coronary angiography is the wide availability;
owever, its accuracy to quantify the capacity of the collat-
ral circulation is limited.
low and pressure measurements in the collateral circulation.
ntracoronary flow and pressure measurements enable more
ccurate measurements of the collateral circulation than
ngiography. Initial clinical studies were based upon mea-
urements of coronary wedge pressure through the fluid-
lled balloon catheter (11). The introduction of ultrathin
uidewires equipped with Doppler crystal and pressure
ensors facilitated assessment of collateral hemodynamics
irectly in the epicardial segment of coronary arteries. The
rst studies were performed with a 0.014-inch Doppler wire
n an angioplasty model in the recipient coronary artery
12). Collateral flow was assessed as an antegrade, retro-
rade, or bidirectional flow velocity signal, depending upon
he position of the guidewire tip (12–14). However, collat-
ral flow can also be assessed in the foster artery as a
ransient flow increase during balloon coronary occlusion
hat corresponds to collateral flow detected in the donor
rtery (15). Collateral flow assessed by blood flow velocity or
edge pressure measurement in the recipient artery ap-
eared to be a better predictor for the occurrence of
ransient myocardial ischemia than angiographic grading of
ollateral vessels (13). Blood flow velocity during balloon
oronary occlusion divided by blood flow velocity after
uccessful angioplasty provides the velocity-derived collat-
ral flow index. In a similar fashion, the development of the
ollateral circulation can be assessed with a pressure guide-
ire to assess the pressure-derived collateral flow indexCFIp) (Fig. 2). CFIp correlates well with velocity-derived
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A Critical Review of Arteriogenesis December 29, 2009/January 5, 2010:17–25ollateral flow index (14). CFIp is easier to apply and has a
etter reproducibility because the signal is not critically
ependent upon the position of the guidewire tip in the
picardial segment. In a study by Pijls et al. (16), it was
emonstrated that a low CFIp (0.23) was associated with
ore ischemic events during 1-year follow-up as compared
ith patients with a high CFIp. Recently, a 10-year
ollow-up study on a large cohort of patients showed low
FIp as an independent prognostic factor for cardiovascular
ortality (17).
Using both flow velocity and pressure measurements in a
arge cohort of patients, Seiler et al. (14) found coronary
esion severity to be the only independent determinant of
ollateral vascular growth. However, the correlation be-
ween lesion severity and CFIp is very weak and virtually
onexistent when leaving out patients with a total coronary
cclusion (18). About two-thirds of patients do not have
ufficient collateral flow to prevent myocardial ischemia
uring coronary occlusion, and this is the group of patients
hat would benefit from a proarteriogenic therapy. On the
ther hand, in patients without significant lesions or even
bsence of visible lesions there is still a large proportion of
atients with a high CFIp (19), suggesting that innate
actors are also responsible for the development of the
ollateral circulation.
Aarnoudse et al. (20) measured real volumetric coronary
ow in patients by using thermodilution. Theoretically, this
llows measurement of absolute collateral flow and resis-
ance rather than flow velocity (20). Future studies have to
etermine the feasibility of this technique for quantification
f collateral flow.
nfluence of vasodilatory substances on collateral flow.
ature collateral arteries respond to administration of
itroglycerin and adenosine (21,22). Following intravenous
dministration of adenosine, coronary collateral steal occurs
n 10% of the patients with nontotal coronary obstructions
nd in one-third of the patients with a chronic total
oronary occlusion (23,24). These studies demonstrate the
easibility of studying the dynamic behavior of the collateral
irculation following pharmacological intervention and us-
ng this technique as a method of choice in clinical studies
n stimulation of collateral artery growth.
ome Insights From Experimental Studies
egree of adaptation. The time for the development of a
rue collateral circulation capable of delivering a sufficient
lood supply is about 3 days in the healthy dog heart.
owever, there is a wide variation within different species
nd even within different strains of the same species (25,26).
he important question is if collateral vascular supply is
ufficient to avoid ischemia under exercise conditions. This
s difficult to study in experimental animals. A generally
ccepted substitute for exercise is the pharmacological in-
uction of vasodilation and the calculation of maximal monductance, which is the reciprocal value of resistance.
n a series of animal studies with chronic progressive
oronary artery occlusions and acute femoral artery oc-
lusion, we could show that about 30% to 40% of the
aximal conductance of a normal artery is restored by
ollateral artery growth (27). This deficit remains con-
tant for the entire lifetime of the animals, and in
xercise-trained mice, this leads to a significant reduction
n their ability to run on a treadmill (25).
tructure and ultrastructure. The first sign in the devel-
pment of collateral vessels is the activation of the endo-
helium (28). Endothelial cells lose osmotic control and
well. Their ultrastructural phenotype changes toward a
roliferative appearance and eventually the cells divide as
an be demonstrated by proliferation markers such as
I-67. At about 12 h after endothelial activation, mono-
ytes adhere to and penetrate the intima and start to digest
he internal elastic lamina by secreting proteases such as
atrix metalloproteinases. This is an important step in the
utward remodeling of collateral arteries, and mitosis of the
mooth muscle cells follows (29) (Fig. 3). Often, a subinti-
al proliferation and accumulation of cells can be observed
hat can reach proportions as to near occlusion of the
ollateral vessel. We explain this as a pruning mechanism.
any pre-existing collateral vessels participate but only a
ew reach mature dimensions; the others degenerate. This
akes sense from a physiological standpoint: minimal
esistance to flow is reached with few large vessels according
o Poiseuille’s law (30).
hear stress as initiator of arteriogenesis. The initiator of
rteriogenesis is increased fluid shear stress. Upon arterial
cclusion, the pressure gradient induces unidirectional flow
rom the high-pressure to the low-pressure region along
re-existing collateral vessels (31). The increased flow leads
o increased fluid shear stress, which is proportional to the
elocity of blood flow. Shear stress acts directly upon gene
xpression involved in the endothelial cell cycle (32). Shear
tress also permits the attraction and adhesion of monocytes
ia endothelial expression of the chemokine monocyte
hemotactic protein (MCP)-1 and the adhesion molecules
ntercellular adhesion molecule-1 and vascular cell adhesion
olecule (33).
Invading monocytes produce the necessary growth fac-
ors, which are probably a complex cocktail of factors. The
rucial role of the monocytes is exemplified by the observa-
ions that genetic targeting of the MCP-1 gene and of the
ene of the MCP-1 receptor (CCR2) leads to a defective
ollateral growth (34,35). Acute reduction of the number of
onocytes in the peripheral blood by bone marrow toxins,
uch as 5-fluorouracil, inhibits arteriogenesis; however,
hen the occlusion is performed during the rebound phase
f monocyte recovery, arteriogenesis is stimulated (36).
Because it is difficult to alter pharmacologically the
ntensity of fluid shear stress, we designed an experiment to
aximize fluid shear stress with a microsurgical operation
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December 29, 2009/January 5, 2010:17–25 A Critical Review of Arteriogenesis37). The femoral artery of rabbits was occluded and the
istal stump was connected side-to-side with the accompa-
ying vein, thereby creating an arteriovenous shunt where
ost of the collateral flow is drained directly into the venous
ystem. The increase in blood flow gives rise to an increase
n collateral growth and with it collateral diameter and
umber, which increased in turn the velocity of flow in a
ositive feedback loop. This experiment showed that the
onductance values 1 week after shunt closure were almost
dentical to the conductance values of the nonoccluded con-
ralateral artery. Four weeks of shunting increased the maximal
onductance to twice the normal value of the nonoccluded
rtery, defining the goal of future drug- or growth-factor
tudies as to reach normal maximal conductance.
he role of ischemia. Arteriogenesis occurs almost always
n the presence of ischemia but arteriogenesis is not caused
y ischemia. This is not always realized because angiogen-
sis, with which arteriogenesis is often confounded, is driven
y ischemia. This is easily observed in hind-leg ischemia:
fter femoral artery occlusion, collateral arteries develop in
he upper leg, surrounded by normally perfused skeletal
uscle, but ischemia and necrosis develop in the foot.
urthermore, collateral arteries are perfused with arterial
lood, and the vascular tissue is sufficiently oxygenized as
hown in experimental as well as clinical studies (38,39).
hat ischemia is not a prerequisite to arteriogenesis was
ecently shown in an elegant approach in a zebra fish
mbryo model (40). In the zebra fish embryo, the tissue
Figure 3 Measurement of CFI
Coronary pressure is first measured proximal to the stenosis (A) and then distal t
calculated according to the formula in the box. Central venous pressure (CVP) is n
higher the distal pressure during balloon inflation and the closer the value of CFI gxygenation is maintained even in the absence of blood lirculation due to diffusion. Gray et al. (40) also showed that
n this model, arterial occlusion leads to formation of
ollateral vessels in the absence of ischemia.
lacebo-Controlled Clinical Studies
n Stimulation of Arteriogenesis
xperimental studies have shown the potential of numerous
xogenously applied growth factors to stimulate collateral
rtery growth. During the last 10 years, these experimental
tudies have been followed up by initial patient studies
iming at modification of collateral artery growth.
ranulocyte-macrophage colony-stimulating factor
GM-CSF). To date, only 1 study (41) specifically sought
o determine the effects of a pro-arteriogenic factor in
oronary artery disease patients using intracoronary mea-
urements on the capacity of the collateral circulation. In
his study, 21 patients were randomized to treatment with
M-CSF or placebo. GM-CSF was earlier shown to be
ro-arteriogenic in a rabbit hind limb model of collateral
rtery growth (42) (Fig. 4). Patients were treated for a
eriod of 14 days with subcutaneously injected GM-CSF in
ddition to a bolus injection at the first examination. CFIp
as measured at days 0 and 14. The increase in CFIp was
ignificantly larger in the treatment group than in the
lacebo group. It should be noted, however, that the effects
epended in part on a single outlier in the treatment group,
howing a particularly strong increase in CFIp. Neverthe-
tenosis during complete balloon occlusion (B). Collateral flow index (CFI) is then
y around 5 mm Hg. The better the development of the collateral circulation, the
1. Pdist  distal pressure; Pprox  proximal pressure.o the s
ormall
ets toess, this was the first and so far only placebo-controlled
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A Critical Review of Arteriogenesis December 29, 2009/January 5, 2010:17–25tudy showing a direct treatment effect on CFIp. A subse-
uent study, which was planned to include a larger group of
atients, showed similar results but was abrogated after the
ccurrence of 2 early stent thromboses in the treatment
roup (42,43). In a placebo-controlled trial in patients with
ntermittent claudication, we found no effect of GM-CSF
n walking distance (44). A specific problem with studies on
M-CSF is the fact that blinding is very difficult because
ide effects are numerous and easily recognized by patients
s well as by physicians/researchers.
ibroblast growth factors (FGFs). Several FGFs have
een used in clinical trials on collateral artery growth.
chumacher et al. (45) published the first patient trial on the
ffects of a growth factor on myocardial vascular growth.
hey performed a randomized placebo-controlled study in
atients undergoing coronary artery bypass grafting of the
AD. All patients had remaining stenoses of the distal
AD, and FGF-1 was injected in close vicinity to the vessel
all. Treated patients showed more contrast accumulation
round the distal LAD, suggestive of increased angiogene-
is. At the same time, treated patients also showed more
etrograde filling of LAD segments distal to the stenosis,
uggesting increased arteriogenesis. Surprisingly, there has
ever been a follow-up study on the effects of FGF-1 in
oronary artery disease patients.
FGF-2 is the most widely studied fibroblast growth
actor, and it has an effect on both angiogenesis and
rteriogenesis (46,47). Only 2 placebo-controlled trials have
een published on the effects of FGF-2. In a small placebo-
ontrolled trial, Laham et al. (48) implanted FGF-2 loaded
ellets in nonrevascularizable territories as an adjuvant to
tandard coronary artery bypass graft. Three months after
mplantation, they observed a decrease in size of the
erfusion defect as assessed by rest thallium/dipyridamole
estamibi imaging in the high-dose FGF-2 group. A large
ubsequent trial studied the effects of a single intracoronary
Figure 4 Proliferating Collateral Artery in the Rabbit Hind Limb
The collateral vessel was fortuitously cut along the longitudinal axis over a relative
cells were detected with an alpha-smooth muscle cell actin antibody (green), and nunfusion of FGF-2 (49). Only at day 90 was there improve- went in the treatment group with regard to symptoms of
ngina. These differences were no longer detectable at day
80. Also, no differences were found between the placebo
nd the treatment groups with regard to exercise treadmill
ime or single-photon emission computed tomography
maging.
The proarteriogenic effects of FGF-4 are much less well
ocumented. In fact, it was only in 2003 that it was shown
y Rissanen et al. (50) that in a rabbit hind limb model the
nfusion of FGF-4 leads to increased collateral flow mainly
ia an increase in diameter of pre-existing collateral chan-
els, that is, arteriogenesis. In patients with stable coronary
rtery disease, a serotype 5 adenovirus encoding for the
GF-4 gene was administered intracoronary with the in-
ention to achieve vessel wall transfection and prolonged
GF-4 release into the coronary system (51). The initial
esults showed a tendency to improved exercise endurance
n a treadmill in patients with poor performance at baseline.
nfortunately, no follow-up angiography or perfusion im-
ging was performed. Also, the effectiveness of the trans-
ection of the vascular wall was unclear. Even in experimen-
al settings, the transfection of endothelium appears to be
xtremely cumbersome. A follow-up trial in a larger group
f patients was abrogated prematurely.
ascular endothelial growth factor. The most widely
tudied growth factor with regard to vascular growth is
ascular endothelial growth factor. This factor is a strong
romoter of angiogenesis (52). Some evidence is also
vailable for effects on arteriogenesis, although this is still
ebated. Positive small patient studies led to the design of a
arge-scale clinical study, the VIVA (Vascular Endothelial
rowth Factor in Ischemia for Vascular Angiogenesis) trial,
hich was also designed from a concept of stimulation of
ngiogenesis. This study failed to show differences between
he treatment and placebo groups for its primary end point,
trajectory. Ki-67 (yellow) was used as a proliferation marker, smooth muscle
taining was performed with Hoechst 33342 (blue). The white bar represents 20 .ly longalking time (53).
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December 29, 2009/January 5, 2010:17–25 A Critical Review of ArteriogenesisReversed Bedside-to-Bench Approach
he growth factors mentioned previously were originally
dentified in experimental models of collateral artery growth
nd then subsequently tested in patient trials in a classic
ench-to-bedside approach. The reversal into a bedside-to-
ench approach is an appealing alternative. The failure of
he clinical trials on arteriogenesis probably relates to the
act that unidentified factors determine the extent of
he outgrowth of collateral arteries in patients. Therefore,
e first have to identify the biological pathways that drive
uman arteriogenesis before designing new clinical trials.
nfortunately, in sharp contrast to the wealth of experi-
ental data, the molecular background of arteriogenesis in
umans is largely unexplored. This can be attributed to the
act that collateral arteries are not accessible in patients for
iopsy, and post-mortem, the identification of collateral
rteries is cumbersome. Monocytes, the circulating cells that
re key players in arteriogenesis, however, are easily obtain-
ble. Previously, we found that patients with a CFIp below
.25 showed decreased monocytic expression of the pro-
rteriogenic factor CD44 (54). This study showed that the
irect comparison of monocytic expression patterns of
atients with either a poor or a well-developed collateral
irculation can lead to the identification of new targets for
timulation of arteriogenesis. We recently elaborated on
hese early findings and performed CFIp measurements in
0 patients with single-vessel coronary artery disease. Tran-
criptome analysis of circulating monocytes provided 246
ifferentially regulated genes between good and bad arte-
iogenic responders. These differences were detected in
onocytes activated by lipopolysaccharide. Resting mono-
ytes did not reveal large differences between the 2 groups.
hus, activation of monocytes, or cellular stress testing as
e refer to it, can reveal differences between good and bad
rteriogenic responders. Pathway analysis showed that es-
ecially genes related to interferon-beta, a type I interferon,
ere up-regulated in bad arteriogenic responders, poten-
ially hampering effective arteriogenesis in these patients.
n a murine hind limb model of arteriogenesis, we indeed
ound an antiarteriogenic effect of exogenously applied
nterferon-beta, thereby completing the bedside-to-bench
pproach (55).
Other groups have also exploited the differences in
rteriogenic response in patients to identify new targets after
omparative transcriptomics. In these studies, only resting
ells were studied (56) or capacity of the collateral circula-
ion was not measured invasively but estimated from angio-
rams (57), which probably explains the relatively low
ifferential expression found in these studies.
onclusions
nsights from studies that were initiated 50 years ago have
aught us that healthy human hearts have an extensive
etwork of pre-existing collateral connections. In the case ofbstructive coronary artery disease, there is an increase in
iameter of these connections and no increase in number or
hange in anatomical distribution. These observations
trongly support the concept of arteriogenesis as outward
emodeling of a pre-existing collateral network.
Substantial progress has been made regarding our insight
nto the dynamic behavior of the collateral circulation in
bstructive coronary artery disease and the potential of
ntracoronary hemodynamic diagnostic techniques to assess
he effect of future treatment modalities aiming to improve
ollateral flow.
The clinical trials on stimulation of arteriogenesis per-
ormed so far did not show benefit. Several factors have
ontributed to the lack of proof for feasibility of therapeutic
rteriogenesis. First, there is a large gap in knowledge on
rteriogenesis between the clinical and experimental set-
ings. Several of the molecular mechanisms underlying the
rocess of arteriogenesis have been unraveled in experimen-
al studies but were never corroborated in clinical studies.
econd, only a very limited number of placebo-controlled
tudies has been performed, which prohibits the acceptance
r the refusal of the concept of therapeutic arteriogenesis at
his time. Third, the clinical studies were initiated at a time
hen it was still widely believed that stimulation of angio-
enesis, which results in increased formation of capillary
etworks, should be the goal. However, in patients with
bstructive coronary artery disease this is most likely not the
ase as the formation of large caliber conductance arteries, as
een during the process of arteriogenesis, is far more efficient
n restoring interrupted blood flow (58). Finally, the previ-
usly mentioned intracoronary techniques for the measure-
ent of the extent of the collateral circulation were never
mployed, with the exception of a single study (41).
Thus, future clinical trials in patients with obstructive
oronary artery disease should be designed, focusing on
rteriogenesis and arteriogenic factors, and efficacy in these
rst trials should be measured using intracoronary measure-
ents of flow and pressure. Preceding future clinical trials,
r at least in parallel with these trials, we have to increase
ur knowledge on the specific molecular mechanisms of ar-
eriogenesis in humans. The availability of high-throughput
enomic or proteomic analysis systems will propel this kind
f research. The integration of this knowledge in the design
f future clinical trials will hopefully lead to the often
eralded, but still not witnessed, clinical implementation of
herapeutic arteriogenesis.
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